Clinical features of polymyalgia rheumatica and giant cell arteritis.
about
Clinical practice. Giant-cell arteritis and polymyalgia rheumaticaThe role of toll like receptors in giant cell arteritisCutaneous nocardiosis manifesting as a frontal mass in a patient with giant cell arteritisA rare case of temporal arteritis with rheumatoid arthritis and interstitial lung disease mimicking pulpo-periodontal pathology.Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patientsEffect of glucocorticoid treatment on computed tomography angiography detected large-vessel inflammation in giant-cell arteritis. A prospective, longitudinal studyImmunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.Giant Cell Arteritis: From Pathogenesis to Therapeutic Management.A Retrospective Study of Chinese Patients With Giant Cell Arteritis (GCA): Clinical Features and Factors Associated With Severe Ischemic ManifestationsGiant Cell Arteritis: Beyond Corticosteroids.Giant Cell Arteritis of the Female Genital Tract With Occult Temporal Arteritis and Marginal Zone Lymphoma Harboring Novel 20q Deletion: A Case Report and Literature Review.Giant cell arteritis: ophthalmic manifestations of a systemic disease.Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation).The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist.Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis.MMP-3 can distinguish isolated PMR from PMR with GCA: A retrospective study regarding PMR and GCA in Japan.Bilateral vertebral artery occlusion without headache in giant cell arteritis.Identification of Herpes Zoster-Associated Temporal Arteritis Among Cases of Giant Cell Arteritis.Increased expression of interleukin-22 in patients with giant cell arteritis.Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis.Early onset polymyalgia rheumatica: two rare cases under age of 50.Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations.Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis.The process from symptom onset to rheumatology clinic in polymyalgia rheumatica.Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study.Comment on: FDG PET in the early diagnosis of large-vessel vasculitis.Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis.MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis.Leg ulcers associated with giant cell arteritis relapse.The Utility of Color Duplex Ultrasonography in the Diagnosis of Giant Cell Arteritis: A Prospective, Masked Study. (An American Ophthalmological Society Thesis).
P2860
Q27005821-654AE7A8-3A2C-47D8-B73E-36BA4DFF4A5FQ28069460-E38B54E0-336A-4174-BC88-4062B7D68FA0Q30355568-FAB940A5-A208-46A2-9AFE-8D86033B86C8Q34153209-FB1A9FA8-EFE2-4409-8279-0EC8DE4335CFQ36150929-E40E99E9-A6DC-4DA1-9FE6-DB86F65A4A72Q36152152-373A4499-F9A3-4EC1-BA93-12C1BF4B7F09Q36484399-C38B61CC-B3EF-40B9-8F91-7B6FDD662E06Q36992669-4ECEA1DB-FB17-4E65-880E-75AC918D59E9Q37205901-BBA3D2CF-D0A6-4F8E-A9B2-50374B2D775DQ38560322-F1705E73-B3F1-450F-8628-661DF4F444F0Q38583653-EC6D8527-D9F9-4C83-AEEE-B1E42536AD62Q38919828-93ADE8AE-BA49-4C56-A96E-5991FC787DB4Q39200766-ABDE98E4-689D-4A1F-9912-6B24CEAB2876Q39275487-14949088-6F60-4C06-9EDA-1B5B2134BC1FQ40065347-C76294DE-F110-49BA-98E7-D1FFA054E387Q41117637-5049E492-A05D-4BEA-ACFA-0A0F85BCBFCFQ42394276-57A40926-AB75-4F2C-A080-35E37AAB7B3DQ47182000-B48E6A65-34D0-417F-87B4-2B37B96BD0B7Q47715350-8C03E4E9-DD2A-46CC-B4EB-F8E1B18C00A5Q51033475-76C54D19-80D2-4833-BD18-1A42C10F507FQ51092032-3175703E-ECBD-4E4C-8EFD-47D7675447E8Q52659244-06AE3533-85CF-4382-A443-4083F0FF0B5BQ52893205-487C55B2-8C6D-43DC-844D-70E968EEFE79Q53066544-3EACD27B-DD2F-4580-B42D-032AD1750D03Q53073312-EFB1B3AE-07CC-46CB-ABE2-A21B19488C35Q53082949-BAE3C96E-94A0-462B-8198-893A146A562DQ53118262-0C7C622F-B23B-4D19-A4B3-F40120218DEFQ53355647-D42542AB-CE72-455D-A4BF-377A76D9ECAAQ54310546-C8F8F517-1CCC-4D47-814E-D6283C0568C7Q55439546-F02C6F83-6F52-4C1F-B9A9-8A09FFA1ADF3
P2860
Clinical features of polymyalgia rheumatica and giant cell arteritis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical features of polymyalgia rheumatica and giant cell arteritis.
@en
type
label
Clinical features of polymyalgia rheumatica and giant cell arteritis.
@en
prefLabel
Clinical features of polymyalgia rheumatica and giant cell arteritis.
@en
P2093
P2860
P356
P1476
Clinical features of polymyalgia rheumatica and giant cell arteritis.
@en
P2093
Annibale Versari
Gene G Hunder
Nicolò Pipitone
P2860
P2888
P304
P356
10.1038/NRRHEUM.2012.97
P407
P577
2012-07-24T00:00:00Z
P6179
1008010543